Jul. 13, 2025 10:45 AM ETNovartis AG (NVS) Stock, NVSEF Stock, NVS:CA StockAZN, NVO, LLY, RHHBY, SNY, PFE, DSKYF, BIIB, SDZNY, IONS, ROG:CA, SDZXF, ROCH:CA, RHHVF, SNYNF, RHHBF, PFE:CA, NVON:CA, NONOF, LLY:CA, DSNKY, AZNCF, NVS, NVSEF, NVS:CAALLKA Research2.43K FollowersSummaryDespite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise.The main contributors to maintaining bullish sentiment towards the Swiss pharmaceutical behemoth are the strong performance of its cardiovascular, oncology, and immunology franchises.For example, sales of its blockbuster Cosentyx amounted to $1.53 billion in the first three months of 2025, up 15.7% year-on-year.Meanwhile, on July 8, Novartis announced that Coartem Baby had been approved by Swissmedic, making it the first drug to treat malaria in newborns and infants.In this article, you will learn about other factors due to which the bulls will continue to maintain the upward trend of Novartis' share price despite certain risks.